BRAF and cutaneous melanoma: We investigated the implication of TSLP in cutaneous melanoma growth and progression, using mouse melanoma models in which tamoxifen (Tam) treatment induces oncogenic BrafV600E expression with or without ablation of the tumor suppressor Pten gene in melanocytes (15, 16), named hereafter Braf/Pten and Braf mice, respectively.